An open-label multicenter study to assess the safety of AVP-923 [dextromethorphan/quinidine; Neurodex (TM)] in the treatment of patients with pseudobulbar affect

Trial Profile

An open-label multicenter study to assess the safety of AVP-923 [dextromethorphan/quinidine; Neurodex (TM)] in the treatment of patients with pseudobulbar affect

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Emotional lability
  • Focus Adverse reactions
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top